National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 20081 [2018-09659]
Download as PDF
<![CDATA[
20081
Federal Register / Vol. 83, No. 88 / Monday, May 7, 2018 / Notices
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total
responses
Total
burden
hours
Rural Health Opioid Program Grant Performance Measures ...................................................................................
10
1
10
11
110
Total ..............................................................................
10
........................
10
........................
110
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Amy P. McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2018–09668 Filed 5–4–18; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
daltland on DSKBBV9HB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel PHS, 2017–1 NIAID Topic 43
(Adjuvant Development).
Date: May 30, 2018.
Time: 10:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Thomas F. Conway, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G51, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, 240–507–9685,
thomas.conway@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
VerDate Sep<11>2014
17:38 May 04, 2018
Jkt 244001
Transfer and Development, 31 Center
Drive Room 4A29, MSC2479, Bethesda,
MD 20892–2479; Telephone: +1–301–
Dated: May 2, 2018.
435–4507; Fax: +1–301–594–3080;
Natasha M. Copeland,
Email: thalhamc@mail.nih.gov.
Program Analyst, Office of Federal Advisory
SUPPLEMENTARY INFORMATION: The
Committee Policy.
following represents the intellectual
[FR Doc. 2018–09659 Filed 5–4–18; 8:45 am]
property to be licensed under the
BILLING CODE 4140–01–P
prospective agreement:
U.S. Provisional Patent Application
No. 61/488,671, filed May 20, 2011; PCT
DEPARTMENT OF HEALTH AND
Application. No. PCT/US2012/028926,
HUMAN SERVICES
filed March 13, 2012; U.S. Patent No.
9,068,003, issued June 30, 2015; U.S.
National Institutes of Health
Patent No. 9,896,511, issued February
Prospective Grant of Exclusive Patent
20, 2018; and U.S. Patent Application
License: Antibodies Against TL1A, a
No. 15/872,592, filed January 16, 2018,
TNF-Family Cytokine, for the
‘‘Antibodies Against TL1A, a TNFTreatment and Diagnosis of Crohn’s
Family Cytokine, for the Treatment and
Disease, Ulcerative Colitis, Asthma,
Diagnosis of Autoimmune Inflammatory
Psoriasis and Biliary Cirrhosis
Diseases’’, NIH Reference No. E–073–
2011/0,1,2.
AGENCY: National Institutes of Health,
With respect to persons who have an
HHS.
obligation to assign their right, title and
ACTION: Notice.
interest to the Government of the United
SUMMARY: The National Heart, Lung, and States of America, the patent rights in
these inventions have been assigned to
Blood Institute (‘‘NHLBI’’), an institute
the Government of the United States of
of the National Institutes of Health; an
agency within the Department of Health America.
The prospective exclusive license
and Human Services, is contemplating
territory may be worldwide and the
the grant of an exclusive patent license
field of use may be limited to the use
to commercialize the invention(s)
of Licensed Patent Rights for the
embodied in the intellectual property
following: ‘‘Development and
estate stated in the Summary
commercialization of antibodies against
Information section of this notice to
TL1A for the treatment and diagnosis of
Precision IBD, Inc., located in San
Crohn’s Disease, Ulcerative Colitis,
Diego, California, and incorporated
Asthma, Psoriasis and Biliary Cirrhosis’’
under the laws of Delaware.
The subject technology is based on
DATES: Only written comments and/or
the use of antibodies against TL1A, a
applications for a license which are
TNF-Family cytokine, for the treatment
received by the NHLBI Office of
and diagnosis of autoimmune
Technology Transfer and Development
inflammatory diseases. Autoimmune
on or before May 22, 2018 will be
inflammatory diseases occur in greater
considered.
than five percent of the U.S. population.
Treatments generally include
ADDRESSES: Requests for copies of the
immunosuppressants or antipatent application, inquiries, and
inflammatory drugs, which can have
comments relating to the contemplated
serious side effects. Recently, more
exclusive license should be directed to:
specific immunomodulatory therapies
Cristina Thalhammer-Reyero, Ph.D.,
such as TNF-alpha antagonists have
MBA, Senior Licensing and Patenting
been developed. In experiments with
Manager, NHLBI Office of Technology
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
E:\FR\FM\07MYN1.SGM
07MYN1
]]>Agencies
[Federal Register Volume 83, Number 88 (Monday, May 7, 2018)]
[Notices]
[Page 20081]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09659]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel PHS, 2017-1 NIAID Topic 43 (Adjuvant
Development).
Date: May 30, 2018.
Time: 10:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Thomas F. Conway, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room 3G51, National Institutes of Health, NIAID, 5601
Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, 240-507-9685,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 2, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-09659 Filed 5-4-18; 8:45 am]
BILLING CODE 4140-01-P
